Overview

A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache

Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax®. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period.
Phase:
Phase 4
Details
Lead Sponsor:
Thomas Jefferson University
Collaborator:
Ortho-McNeil Neurologics, Inc.
Treatments:
Topiramate